NASDAQ:INDV Indivior (INDV) Stock Price, News & Analysis $10.35 -0.74 (-6.67%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.32▼$11.0450-Day Range$10.19▼$15.7552-Week Range$9.14▼$23.22Volume1.80 million shsAverage Volume315,758 shsMarket Capitalization$1.43 billionP/E Ratio1,035.00Dividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Indivior alerts: Email Address Indivior MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.2% Upside$23.00 Price TargetShort InterestHealthy0.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 16 Articles This WeekInsider TradingN/AProj. Earnings Growth20.69%From $1.74 to $2.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector265th out of 910 stocksPharmaceutical Preparations Industry111th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days.Read more about Indivior's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.17% of the float of Indivior has been sold short.Short Interest Ratio / Days to CoverIndivior has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indivior has recently decreased by 53.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDV. Previous Next 1.7 News and Social Media Coverage News SentimentIndivior has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Indivior this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock.Percentage Held by Institutions60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Indivior's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Indivior are expected to grow by 20.69% in the coming year, from $1.74 to $2.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is 1,035.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is 1,035.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Read more about Indivior's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Indivior Stock (NASDAQ:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesSeptember 6 at 8:00 PM | prnewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud LawsuitSeptember 6 at 5:45 AM | prnewswire.comShareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDVSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 5 at 6:30 PM | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)September 5 at 4:00 PM | globenewswire.comINDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!September 5 at 2:17 PM | globenewswire.comShareholders that lost money on Indivior PLC (INDV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreSeptember 5 at 1:26 PM | globenewswire.comROSEN, A TOP-RANKED LAW FIRM, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action – INDVSeptember 5 at 5:45 AM | prnewswire.comIndivior PLC Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - INDVSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 4 at 4:55 PM | prnewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud LawsuitSeptember 4 at 3:18 PM | prnewswire.comRosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their RightsSeptember 4 at 2:34 AM | markets.businessinsider.comROSEN, A LONGSTANDING LAW FIRM, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action - INDVSeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDVSeptember 3, 2024 | prnewswire.comContact Levi & Korsinsky by October 1, 2024 Deadline to Join Class Action Against Indivior PLC(INDV)September 1, 2024 | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Indivior PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action – INDVAugust 30, 2024 | prnewswire.comINDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud LawsuitAugust 30, 2024 | globenewswire.comINDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!August 30, 2024 | globenewswire.comIndivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff MotionSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/25/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDV CUSIPN/A CIK1625297 Webwww.indivior.com Phone804-379-1090Fax804-379-1215Employees1,164Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$24.00 Low Stock Price Target$22.00 Potential Upside/Downside+122.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio1,035.00 Forward P/E Ratio5.95 P/E GrowthN/ANet Income$2 million Net Margins-12.29% Pretax Margin-16.65% Return on Equity-654.82% Return on Assets13.01% Debt Debt-to-Equity Ratio23.50 Current Ratio0.85 Quick Ratio0.68 Sales & Book Value Annual Sales$1.15 billion Price / Sales1.24 Cash Flow$1.51 per share Price / Cash Flow6.87 Book Value($0.88) per share Price / Book-11.76Miscellaneous Outstanding Shares137,879,000Free FloatN/AMarket Cap$1.43 billion OptionableNot Optionable Beta0.68 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXGrifolsNASDAQ:GRFSCytokineticsNASDAQ:CYTKBridgeBio PharmaNASDAQ:BBIOBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 162,800 shares on 8/16/2024Ownership: 0.000%Mackenzie Financial CorpSold 57,185 shares on 8/15/2024Ownership: 0.361%Millennium Management LLCBought 160,282 shares on 8/15/2024Ownership: 0.358%AXA S.A.Sold 37,254 shares on 8/15/2024Ownership: 0.175%The Manufacturers Life Insurance Company Sold 1,223 shares on 8/15/2024Ownership: 0.010%View All Institutional Transactions INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at $15.27 at the beginning of 2024. Since then, INDV stock has decreased by 32.2% and is now trading at $10.35. View the best growth stocks for 2024 here. How were Indivior's earnings last quarter? Indivior PLC (NASDAQ:INDV) posted its earnings results on Thursday, July, 25th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.04. The business earned $299 million during the quarter, compared to analysts' expectations of $285.90 million. Indivior had a negative net margin of 12.29% and a negative trailing twelve-month return on equity of 654.82%. Who are Indivior's major shareholders? Top institutional investors of Indivior include Liontrust Investment Partners LLP (0.99%), Toronto Dominion Bank (0.83%), Mackenzie Financial Corp (0.36%) and Millennium Management LLC (0.36%). How do I buy shares of Indivior? Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.